In terms of industry tailwinds, Trump could lessen pressure from the Federal Trade Commission on mergers and acquisitions, ...

Q3 2024 Earnings Call Transcript November 7, 2024 Operator: Good morning, everyone, and welcome to the Viatris Q3 2024 Earnings Call. All participants will be in a listen-only mode. [Operator ...

In recent trading, Lexicon Pharmaceuticals Inc (LXRX) stock price has shown some volatility, fluctuating -33.33% over the last five trades and -22.62% over the past 30 trades. This represents a ...

Key Takeaways The S&P 500 added 0.7% on Thursday, Nov. 7, 2024, as the Fed announced a quarter-point interest-rate cut, in ...

Drugmaker Viatris beat Wall Street estimates for third-quarter profit and revenue on Thursday, helped by strong demand for its new generic asthma and ADHD drugs, among others, sending its shares up 2.

Independent advisers to the FDA voted against recommending Lexicon Pharmaceuticals‘ add-on treatment to insulin therapy for ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 3.44% of ...

The FDA panel voted against the approval of sotagliflozin for patients with type 1 diabetes and chronic kidney disease.

A live audio webcast of the fireside chat presentation will be available at https://wsw.com/webcast/guggen/kros/1967811 and ...

After multiple rejections, Lexicon Pharmaceuticals is inching toward an FDA decision date next month for its adjunct type 1 ...

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies London Global Healthcare Conference. Lexicon management including Mike Exton, Lexicon’s chief executive ...